
Akero Therapeutics AKRO
Quarterly report 2025-Q3
added 11-07-2025
Akero Therapeutics Total Current Liabilities 2011-2026 | AKRO
Annual Total Current Liabilities Akero Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39.8 M | 19.1 M | 19.1 M | 25.1 M | 13.1 M | 9.37 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 39.8 M | 9.37 M | 20.9 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Happiness Biotech Group Limited
HAPP
|
6.4 M | - | 1.35 % | $ 17.8 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
158 M | $ 16.88 | -2.43 % | $ 789 M | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
Compugen Ltd.
CGEN
|
22.6 M | $ 2.79 | -8.09 % | $ 261 M | ||
|
Coherus BioSciences
CHRS
|
140 M | $ 1.6 | -2.15 % | $ 187 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
36.4 M | $ 7.56 | -3.45 % | $ 207 M | ||
|
Athira Pharma
ATHA
|
47.5 M | - | - | $ 269 M | ||
|
Galera Therapeutics
GRTX
|
645 K | - | -32.59 % | $ 7.61 M | ||
|
Esperion Therapeutics
ESPR
|
301 M | $ 3.13 | 0.32 % | $ 651 M | ||
|
Exelixis
EXEL
|
406 M | $ 50.41 | -1.36 % | $ 13.7 B | ||
|
Fortress Biotech
FBIO
|
49.7 M | $ 2.43 | 5.65 % | $ 67.8 M | ||
|
Forte Biosciences
FBRX
|
20.8 M | $ 23.1 | -3.57 % | $ 299 M | ||
|
Fennec Pharmaceuticals
FENC
|
10.5 M | $ 9.76 | 5.63 % | $ 279 M | ||
|
AbCellera Biologics
ABCL
|
64.3 M | $ 4.09 | -7.05 % | $ 1.22 B | ||
|
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.59 | - | $ 423 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | ||
|
Galectin Therapeutics
GALT
|
8.03 M | $ 2.22 | -5.74 % | $ 142 M | ||
|
Gilead Sciences
GILD
|
11.8 B | $ 130.07 | -1.51 % | $ 162 B | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 3.41 | -2.25 % | $ 5.61 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
9.02 M | $ 0.72 | -1.05 % | $ 32.9 M | ||
|
Eton Pharmaceuticals
ETON
|
38.5 M | $ 29.69 | -0.92 % | $ 799 M | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
130 M | $ 21.51 | -0.3 % | $ 2.74 B | ||
|
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M |